Immunogenicity and reactogenicity of acellular pertussis booster vaccines in children: standard pediatric versus a reduced-antigen content formulation.

Abstract

Booster vaccination with a reduced-antigen-content dTpa, pediatric DTPa or adult Td vaccine in DTPa-primed children aged 4-6 years was evaluated. Immunogenicity and CMI was assessed one month and 3.5 years after vaccination. Symptoms were solicited for 15 days post-vaccination. There were no differences between groups in diphtheria or tetanus seroprotection or pertussis vaccine-response rates. Anti-diphtheria and anti-PRN concentrations were higher after DTPa, but groups differences reduced over time. Non-significant trends toward reduced reactogenicity of dTpa were observed. Many factors influence vaccine choice at preschool age. The dTpa vaccine was as immunogenic and possibly better tolerated than DTPa at this age.

• Authors: Claudius U Meyer, Pirmin Habermehl, Markus Knuf, Bernhard Hoet, Joanne Wolter, Fred Zepp
• Journal: Human vaccines (Hum Vaccin) 2008 May-Jun Vol. 4 Issue 3 Pg. 203-9 ISSN: 1554-8619 [Electronic] United States
• PMID: 18382142 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Bacterial
• Antigens, Bacterial
• Pertussis Vaccine
• Vaccines, Acellular

Topics

• Antibodies, Bacterial (blood)
• Antigens, Bacterial (adverse effects, immunology)
• Child
• Child, Preschool
• Diphtheria (immunology, prevention & control)
• Female
• Germany
• Humans
• Immunization, Secondary (methods)
• Male
• Pertussis Vaccine (adverse effects, immunology)
• Tetanus (immunology, prevention & control)
• Vaccines, Acellular (adverse effects, immunology)
• Whooping Cough (immunology, prevention & control)